Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Piramal acquires...

    Piramal acquires Digeplex from Shreya Lifesciences

    Written by Ruby Khatun Khatun Published On 2017-12-01T11:00:24+05:30  |  Updated On 18 Aug 2021 3:30 PM IST

    MUMBAI: Piramal Enterprises acquired the Digeplex and the associated brands from Shreya Lifesciences for an undisclosed sum to expand its consumer products business.


    The acquisition will help the Ajay Piramal-led company expand its gastrointestinal product portfolio.


    "We believe Digeplex and its associated brands are a strategic fit for our portfolio that will help us move closer towards our stated objective," executive director Nandini Piramal said.


    She said the company's aim is to be a significant player in the healthcare segment and this acquisition is an important route for the same and in the last two years, it has completed three such transactions in the consumer products business alone.


    The combination of organic growth and acquisitions has helped the company create a powerful over the counter portfolio of brands in the country, she added.


    Chief operating officer for the consumer products division Kedar Rajadnye said the gastrointestinal market comprising constipation, diarrhoea, and appetite stimulant categories, is a Rs 13,000-crore opportunity which has been clipping at 11 percent every year.


    He claimed the company already has established antacid brands of Polycrol, and Naturolax, an isabgol husk based brand which helps in treating constipation and the acquisition will help it enlarge the offerings.


    In a statement, the company said the acquisition will leverage the strong sales and its distribution capability and help improve profit margins.


    Piramal Enterprises' scrip was trading 0.73 per cent down at Rs 2,784.75 a piece on the BSE, as against 0.64 per cent correction in the benchmark.

    AcquiresAcquisitionAjay Piramalantacidconstipationconsumer products businessdiarrhoeaDigeplexgastrointestinalHealthcareisabgol huskKedar RajadnyeNandini PiramalNaturolaxPiramalPiramal enterprisesPolycrolproduct portfolioShreya Lifesciences
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok